Cell Genesys news from FierceBiotech
News
GVAX questions depress Dendreon shares
After halting one GVAX study so it could further investigate a disturbing number of deaths, Cell Genesys' hopes for the vaccine are now focused on a separate Phase III trial that has not raised the Read more...
Deaths force halt to Cell Genesys cancer vaccine trial
A closely watched trial for Cell Genesys' prostate cancer vaccine GVAX was brought to a sudden halt after an independent monitoring committee noted a significantly higher death rate in the group Read more...
Takeda makes $8.8B bid for Millennium
Looking to expand out of a budget-bound Japanese market, Takeda is taking a big chunk of its $10 billion war chest and offering $8.8 billion in cash for U.S.-based Read more...
Takeda makes $8.8B bid for Millennium
Looking to expand out of a budget-bound Japanese market, Takeda is taking a big chunk of its $10 billion war chest and offering $8.8 billion in cash for U.S.-based Read more...
Cell Genesys scores $320M blockbuster deal
Japan's Takeda Pharmaceutical will pay Cell Genesys $50 million upfront and up to $270 million more for hitting Read more...
C&L: Stonehouse tapped to run Biocryst
BioCryst Pharmaceuticals announced that Jon P. Stonehouse, has been appointed CEO and a member of the company's board of directors. Stonehouse succeeds Charles E. Bugg, Ph.D., founder and former CEO who previously announced his intention to retire in 2007. In his new role, Dr. Bugg will become non-executive chairman of …
Read more...C&L: Cell Genesys COO Vallner resigns
Cell Genesys announced that Joseph J. Vallner, Ph.D., the company's president and COO, has resigned to become the CFO of an early-stage, private biotechnology company.
Le@p Technology has named Dr. Donald J. Ciappenelli as CEO and chairman.
Access Genetics has named industry veteran …
Read more...Blair touts biotech biz in San Francisco sit-down
Singling out Genentech for high praise, British Prime Minister Tony Blair sat down with a group of biotech execs in San Francisco yesterday to highlight his own commitment to boosting Britain's drug development industry. In a marked break with the Bush administration, Blair also emphasized the need for more research work in embryonic stem cells. A number of British biotech officials feel their country's research groups have stolen a march on the U.S., pushing ahead while stem cell work in …
Read more...ALSO NOTED: Cadence files $86.3M IPO; Chutes & Ladders: Merck exec steps down; and much more...
> Yesterday, Cadence Pharmaceuticals filed an $86.3 million IPO with the SEC. The company currently has two Phase III products in development. Release
> Cangene today has filed an NDA for its recombinant human growth hormone product (rhGH) Accretropin with the FDA. Accretropin combats short stature in children with growth hormone deficiency and girls with Turner Syndrome. …
Read more...ALSO NOTED: Nektar gains fast track for lung infection drug; Vertex reports positive hep C data; and much more...
> Nektar Therapeutics was given a fast-track designation for its lung infection prevention drug. Report
> Vertex announced that all 12 patients in a mid-stage trial of its VX-950 hepatitis C therapy showed no detectable signs of the virus after 28 days of therapy. Report
> ViroPharma announced …
Read more...Get more Cell Genesys coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets